April 7, 2017 10:27 AM EDT
News Briefing

J&J inks a $1.15B dis­cov­ery deal with Pep­tiDream; Medi­vir plots PhI­II HDAC pro­gram

Shehla Shakoor

Managing Director

→ Tokyo-based Pep­tiDream has struck a dis­cov­ery deal with J&J worth up to $1.15 bil­lion. In the deal Pep­tiDream will use its plat­form tech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times